Welcome to our dedicated page for bli news (Ticker: bli), a resource for investors and traders seeking the latest updates and insights on bli stock.
Berkeley Lights, Inc. operates as a leading biotechnology company dedicated to providing cutting-edge technology solutions for single-cell manipulation. The company's innovative platform facilitates advancements in biopharma, diagnostics, and life science research. Berkeley Lights leverages its proprietary OptoSelect™ technology to enable precise control over biological processes at the single-cell level.
Headquartered in the United States, Berkeley Lights serves a global customer base, including leading pharmaceutical companies, research institutions, and diagnostics firms. The company's technology empowers researchers to discover new drugs, create better diagnostics, and develop innovative therapies.
One of the notable recent achievements of Berkeley Lights is the expansion of its platform capabilities, enhancing the efficiency and accuracy of single-cell analysis. The company has also formed strategic partnerships with key industry players to drive further innovation and market reach.
Financially, Berkeley Lights continues to show robust performance, with steady revenue growth and strategic investments in research and development. The company is committed to maintaining a strong financial position to support its mission of advancing human health through groundbreaking biotechnological solutions.
Current projects include the development of advanced cell therapy applications and expanding the use of their technology in various research and clinical settings. These projects highlight Berkeley Lights' commitment to pushing the boundaries of what's possible in biotechnology.
Overall, Berkeley Lights, Inc. stands at the forefront of biotechnology, offering unparalleled solutions for single-cell research and manipulation. The company's dedication to innovation and quality makes it a significant player in the life sciences sector.
Berkeley Lights, Inc. (BLI) reported record preliminary revenue for Q3 2021, with an estimated total between $24.0 million and $24.3 million, marking a growth of approximately 33% compared to Q3 2020's revenue of $18.2 million.
The company achieved 13 new platform placements in the quarter, including three subscriptions booked in the prior quarter. The positive results underline robust demand for its technology, with the full financial results expected on November 4, 2021.
Berkeley Lights, Inc. (Nasdaq: BLI) announces that Genovac, a leading contract research organization, becomes the first CRO to use the Beacon system for both antibody discovery and cell line development. This strategic expansion allows for accelerated workflows, reducing the start-up time for CLD processes by up to six months. Genovac cites enhanced success rates against challenging targets and aims to deliver high-producing cell lines for therapeutic manufacturing. This initiative was partially funded by a Bioscience Innovation Grant from the North Dakota Department of Agriculture.
Berkeley Lights, Inc. (Nasdaq: BLI) announced the appointment of Siddhartha Kadia, Ph.D. as an independent director, effective September 7, 2021. Dr. Kadia brings extensive leadership experience from previous roles including CEO of EAG Laboratories and senior positions at Life Technologies Corporation. His expertise in commercializing disruptive life science technologies is expected to enhance Berkeley Lights' strategic direction. CEO Eric Hobbs expressed confidence that Dr. Kadia will significantly contribute to the company’s efforts to transform the biology market and deliver value to shareholders.
Berkeley Lights (Nasdaq: BLI) will participate virtually in the Morgan Stanley Global Healthcare Conference on September 9, 2021. The management is scheduled for a fireside chat at 7:15 a.m. PT / 10:15 a.m. ET. A live and archived webcast will be accessible through the company's website under the 'Investors' section.
Berkeley Lights specializes in Digital Cell Biology, offering advanced solutions for developing biotherapeutics. Its platform provides comprehensive analysis of single cells, enhancing the rapid commercialization of cell-based products.
Berkeley Lights, Inc. (Nasdaq: BLI) reported a second-quarter revenue of $19.3 million, marking an impressive 82% increase year over year. The first half of 2021 also saw revenue of $37.9 million, up 56% from the previous year. The company expanded its installed base to 92 platforms and launched the TechAccess subscription model. Notably, a partnership with Bayer aims to screen bioactive variants using Berkeley Lights' technology, creating multi-year revenue opportunities. Despite the growth, the company reported a net loss of $18.2 million for the quarter.
Berkeley Lights has announced a multi-year agreement with Bayer Crop Science to develop high-throughput functional screening workflows. This partnership aims to enhance the discovery of novel traits in Bayer's seeds and traits pipeline. Berkeley Lights will utilize its proprietary platform to efficiently screen bioactive variants, significantly accelerating Bayer's research capabilities. This marks the entry of Berkeley Lights' technology into the agricultural sector, showcasing its potential application beyond agriculture to areas like pharmaceuticals and biotechnology.
Berkeley Lights, Inc. (Nasdaq: BLI) has formed a strategic collaboration with Thermo Fisher Scientific to enhance viral vector manufacturing. Initiated in December 2020, this partnership combines Berkeley Lights' functional biology capabilities with Thermo Fisher's manufacturing expertise. The collaboration aims to create a next-generation workflow to develop stable AAV and Lentiviral vector producer cell lines, overcoming limitations of transient expression. This advancement is crucial for the rapid, scalable production of cell and gene therapies, benefiting a broader patient population.
Berkeley Lights, Inc. (Nasdaq: BLI) will release its second quarter 2021 financial results on August 11, 2021, before market opening. A live conference call will follow at 5:30 a.m. PT / 8:30 a.m. ET, accessible via the company's website. Berkeley Lights specializes in Digital Cell Biology, focusing on the rapid development of biotherapeutics and cell-based products. The company's integrated platform captures extensive data from single cells, offering advanced solutions for functional characterization in the biotechnology sector.
Berkeley Lights, Inc. (Nasdaq: BLI) announced the launch of its TechAccess Subscription model, aimed at enhancing customer access to its single-cell screening technology. This subscription offers flexibility in volume and throughput, providing essential services like cell line development and antibody discovery without upfront costs. Each subscription lasts for one year, granting access to advanced technologies and features. The company has begun signing agreements for this model, meeting customer demand for tailored access and potentially broadening its market reach.
Berkeley Lights (Nasdaq: BLI) will participate virtually in the William Blair 41st Annual Growth Stock Conference on June 1, 2021. The management is set for a fireside chat at 10:40 a.m. PT / 1:40 p.m. ET. The event will be accessible via a live and archived webcast on their website. Berkeley Lights specializes in Digital Cell Biology and aims to revolutionize biotherapeutics through innovative platforms.
FAQ
What is the market cap of bli (bli)?
What does Berkeley Lights, Inc. do?
Who are the customers of Berkeley Lights?
What is OptoSelect™ technology?
Has Berkeley Lights achieved any recent milestones?
What are Berkeley Lights' current projects?
How is Berkeley Lights performing financially?
Where is Berkeley Lights headquartered?
What impact does Berkeley Lights have on the biotechnology sector?
What is the significance of their technology in biopharma?
Who are some of Berkeley Lights' strategic partners?
